Literature DB >> 11869845

The role of vitronectin receptor (alphavbeta3) and tissue factor in the pathogenesis of transplant coronary vasculopathy.

Mohamad H Yamani1, Carolina S Masri, Norman B Ratliff, Meredith Bond, Randall C Starling, E Murat Tuzcu, Patrick M McCarthy, James B Young.   

Abstract

OBJECTIVES: This study was undertaken to test the hypothesis that transplant coronary vasculopathy (CV) is associated with increased myocardial protein expression of both tissue factor (TF) and integrin alphavbeta3.
BACKGROUND: The vitronectin receptor (integrin alphavbeta3) and TF have recently been found to play a key role in apoptotic cell death and vascular endothelial cell injury.
METHODS: A total of 77 heart transplant recipients underwent simultaneous endomyocardial biopsy and intravascular ultrasound (IVUS) at one year of transplant. Patients with pre-existing donor coronary atherosclerosis (n = 35) or with acute rejection (grade >1A, n = 10) at the time of the IVUS were excluded from the analysis. The remaining 32 patients constitute the cohort of the present study. A computerized biopsy score was derived based on the duration and severity of cellular rejection. Both TF and alphavbeta3 expression in the heart biopsy specimens were evaluated by immunoperoxidase histochemistry and Western blot analysis.
RESULTS: Patients with CV (n = 24) had increased expression of alphavbeta3 (2.7-fold, p = 0.003) and TF (7.9-fold, p = 0.04) compared with patients without evidence of vasculopathy (n = 8). In the absence of myocardial fibrosis, alphavbeta3 expression correlated significantly with the cellular rejection score (r = 0.58, p = 0.02).
CONCLUSIONS: Transplant vasculopathy is associated with increased expression of both TF and alphavbeta3. The significant correlation of alphavbeta3 with cellular rejection suggests an important role for this integrin in serving as a mechanistic link between cellular rejection and vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11869845     DOI: 10.1016/s0735-1097(01)01823-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  Anti-inflammatory effects of alphav integrin antagonism in acute kidney allograft rejection.

Authors:  Jens Bedke; Eva Kiss; Carl-Ludwig Behnes; Zoran V Popovic; Markus Heuser; Tomislav Stojanovic; Tjeerd Sijmonsma; Peter Huber; Sophie Domhan; Stefan Muschal; Amir Abdollahi; Norbert Gretz; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2007-08-16       Impact factor: 4.307

Review 2.  The link between major histocompatibility complex antibodies and cell proliferation.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Transplant Rev (Orlando)       Date:  2011-07-30       Impact factor: 3.943

3.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

Authors:  Jihong Li; Yoshiyuki Fukase; Yi Shang; Wei Zou; José M Muñoz-Félix; Lorena Buitrago; Johannes van Agthoven; Yixiao Zhang; Ryoma Hara; Yuta Tanaka; Rei Okamoto; Takeshi Yasui; Takashi Nakahata; Toshihiro Imaeda; Kazuyoshi Aso; Yuchen Zhou; Charles Locuson; Dragana Nesic; Mark Duggan; Junichi Takagi; Roger D Vaughan; Thomas Walz; Kairbaan Hodivala-Dilke; Steven L Teitelbaum; M Amin Arnaout; Marta Filizola; Michael A Foley; Barry S Coller
Journal:  ACS Pharmacol Transl Sci       Date:  2019-08-02

4.  Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study.

Authors:  R C Starling; J Stehlik; D A Baran; B Armstrong; J R Stone; D Ikle; Y Morrison; N D Bridges; P Putheti; T B Strom; M Bhasin; I Guleria; A Chandraker; M Sayegh; K P Daly; D M Briscoe; P S Heeger
Journal:  Am J Transplant       Date:  2015-08-10       Impact factor: 8.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.